

# 9<sup>th</sup> SSRHR Meeting



Scientific Society  
of Research in  
Human Reproduction

Under the Auspices



Hellenic Obstetrical  
and Gynecological  
Society



MSRM  
Mediterranean  
Society for  
Reproductive  
Medicine



Medical  
Association  
of Heraklion



University  
of Crete

Meeting Chairman

**Prof. Antonios Makrigiannakis**

## Controversies in Human Reproduction



**10 October**  
**12 2025**

**Heraklion, Crete**  
IBIS STYLE HOTEL

ssrhrmeetings.com



# Final Program

# CONTENTS

---

<b>WELCOME MESSAGE</b>	<b>3</b>
<b>COMMITTEES</b>	<b>4</b>
<b>FACULTY</b>	<b>5</b>
<b>SCIENTIFIC PROGRAM</b>	<b>6</b>
<b>INDUSTRY SESSIONS</b>	<b>12</b>
<b>GENERAL INFORMATION</b>	<b>15</b>
<b>ACKNOWLEDGEMENTS</b>	<b>17</b>

---





# WELCOME MESSAGE



Dear Colleagues and Friends,

It is with great pleasure that I welcome you to the **9th SSRHR Meeting: “Controversies in Human Reproduction”**, taking place in Heraklion, Crete, from **October 10–12, 2025**.

On behalf of the Organizing Committee, we are honored to host this distinguished gathering of experts, clinicians, researchers, and professionals from around the world. This meeting provides a unique platform for open, interdisciplinary dialogue on the most pressing and debated topics in the field of human reproduction — from the latest advances in assisted reproductive technologies to ethical dilemmas and policy challenges.

We believe that your presence and contributions will greatly enrich the scientific discussion and help shape the future of reproductive medicine.

We look forward to engaging discussions, meaningful collaborations, and a memorable experience here in Crete.

Warm regards,


**Professor Antonios Makrigiannakis**  
MD, PhD, Meeting Chair



# COMMITTEES

## Scientific Committee

Antonis Makrigiannakis  
Anis Feki  
Hassan Sallam  
Ioannis Messinis  
Dimitrios Loutradis




## Organising Committee

Antonis Makrigiannakis  
Paris Anagnostopoulos  
Georgios Andreadakis  
Maria Asmarianaki  
Aikaterini Berdiaki  
Maria Charitou  
Dimitrios Koutroulakis  
Ioannis Drakakis  
Georgia Iakovidou  
Konstantina Kaligianni  
Spyridon Koustas

Dimitrios Koutroulakis  
Fanourios Makrygiannakis  
Vasilis G. Mytaras  
Maria Papastamatiou  
Maria Rasidaki  
Amalia Savvidi  
Ismeni Tzanaki  
Alexandros Velegrakis  
Zoi Volonaki  
Thomas Vrekoussis



# FACULTY



- 
- A** Anagnostaki Athina, *Greece*  
Antonakis Georgios, *Greece*  
Asmarianni Maria, *Greece*
- 
- B** Benkhalifa Moncef, *France*  
Berdiaki Aikaterini, *Greece*
- 
- C** Chrousos Georgios, *Greece*
- 
- D** Dafopoulos Konstantinos, *Greece*  
Daponte Alexandros, *Greece*  
Daskalakis Georgios, *Greece*  
De Bree Eelco, *Greece*  
Domali Ekaterini, *Greece*  
Drakakis Ioannis, *Greece*  
Drakakis Petros, *Greece*
- 
- E** El Borgini Alexandra, *Greece*
- 
- F** Feki Anis, *Switzerland*
- 
- G** Gerente Angeliki, *Greece*  
Grimbizis Grigorios, *Greece*
- 
- H** Hatzidaki Eleni, *Greece*
- 
- J** Jeschke Udo, *Germany*
- 
- K** Kalantaridou Sophia, *Greece*  
Klentzeris Lucas D., *Greece*  
Kolibianakis Efstratios, *Greece*
- 
- L** Lainas Georgios, *Greece*  
Loutradis Dimitrios, *Greece*
- 
- M** Makrakis Evangelos, *Greece*  
Makrygiannakis Antonios, *Greece*  
Makrygiannakis Fanourios, *Greece*  
Marmara Maria, *Greece*  
Messini Christina, *Greece*  
Messinis Ioannis, *Greece*  
Muller D. Michael, *Switzerland*
- 
- N** Nikolaou Marinos, *Greece*
- 
- P** Papadaki Eleni, *Greece*  
Papaioannou Georgios, *Greece*  
Parasiri Eirini-Ismini, *Greece*  
Pelagiadis Ioannis, *Greece*  
Petousis Stamatios, *Greece*  
Pirtea Paul, *France*
- 
- R** Rodolakis Alexandros, *Greece*
- 
- S** Sakaveli Olympia, *Greece*  
Sakellarakis Georgios, *Greece*  
Sallam Hassan, *Egypt*  
Sfakianoudis Konstantinos, *Greece*  
Sousos Nikolas, *Greece*  
Stavrou Sofoklis, *Greece*  
Stiakaki Effichia, *Greece*
- 
- T** Tarlantzis Basil, *Greece*  
Terzakis Georgios, *Greece*  
Tzormpatzaki Anastasia, *Greece*
- 
- V** Velegrakis Antonios, *Greece*  
Venetis Christos, *Greece*  
Vergadi E., *Greece*  
Vlahos Nikolaos, *Greece*  
Vrekoussis Thomas, *Greece*

FRIDAY 10 | 10 | 2025

10.00

## REGISTRATIONS

11.00 - 12.30

## ORAL PRESENTATIONS I

Chairs: **Berdiaki A., Vrekoussis T.**

OP1

**Ageing reulates receptivity of the human endometrium**

**Panagiota Meramveliotaki**<sup>1</sup>, Fanourios Makrygiannakis<sup>1,2</sup>, Maria Marmara<sup>1,2</sup>, Thomas Vrekoussis<sup>2</sup>, Dragana Nikitovic<sup>1</sup>, Antonios Makrigiannakis<sup>2</sup> and Aikaterini Berdiaki<sup>1</sup>  
<sup>1</sup>University of Crete, School of Medicine, Division of Morphology, Department of Histology-Embryology, University of Crete. Heraklion, Greece, <sup>2</sup>Department of Obstetrics and Gynecology, Laboratory of Human Reproduction, University of Crete, Heraklion, Greece

OP2

**Management of a rare case of C3 glomerulopathy during pregnancy: A case-based review**

**K. Kalligianni Sofikiti**<sup>1</sup>, F. Makrygiannakis<sup>1</sup>, I. Tzanaki<sup>1</sup>, M. Rasidaki<sup>1</sup>, S. Koustas<sup>1</sup>, G. Andreadakis<sup>1</sup>, A. Makrigiannakis<sup>1</sup>  
<sup>1</sup>Department of Obstetrics & Gynecology, University Hospital Heraklion, Greece, Heraklion Crete, Greece

OP3

**Placenta Previa cases management: Cases report and literature review**

**M. Charitou**, G. Iakovidou, I. Tzanaki, K. Kalligianni, F. Makrygiannakis, G. Andreadakis, T. Vrekoussis., A. Makrigiannakis  
 Department Of University Hospital Of Crete

OP4

**Recognition and management of hellp syndrome in the second trimester: a rare clinical case report**

**E. Kouloulia**, K. Kalligianni, A. Kouvalakis, V. Mytaras, M. Rasidaki, A. Makrigiannakis  
 Obstetrics And Gynaecology Department Of University Hospital Of Crete

OP5

**A plot twist in late pregnancy: Incomplete ovarian torsion presenting as acute abdomen. Case report and literature review**

**Alexandros Kouvalakis**, Eleni Kouloulia, Ismini Tzanaki, Georgios Lamprakos, Georgios Andreadakis, Antonios Makrigiannakis  
 University Hospital of Heraklion, Crete, Greece

OP6

**Basal Cell Cancer of the Vulva: Case report and literature review**

**Iakovidou G.**, Lamprakos G., Charitou M., Volonaki Z., Vrekoussis T., Makrigiannakis A.  
 Obstetrics And Gynaecology Department Of University Hospital Of Crete

OP7

**Ovarian rejuvenation: clinical profile**

**Khaled Salech**<sup>2</sup>, Spyridon Topis<sup>1</sup>, Ioannis Arkoulis<sup>1</sup>, Petros-Pavlos Nikolopoulos<sup>2</sup>, Argyro Papadopoulou<sup>2</sup>, Anastasios Potiris<sup>1</sup>, Peter Drakakis<sup>1</sup>, Ekaterini Domali<sup>2</sup>, Sofia Anysiadou, Sofoklis Stavros<sup>1</sup>  
<sup>1</sup>Third Department of Obstetrics and Gynecology, University General Hospital "ATTIKON", Medical School, National and Kapodistrian University of Athens, Athens, Greece.  
<sup>2</sup>First Department of Obstetrics and Gynecology, Alexandra Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

OP8

**Vaginal strengthening (PRP): an alternative method for treating vaginitis?**

**Petros-Pavlos Nikolopoulos**<sup>2</sup>, Spyridon Topis<sup>1</sup>, Ioannis Arkoulis<sup>1</sup>, Petros-Pavlos Nikolopoulos<sup>2</sup>, Argyro Papadopoulou<sup>2</sup>, Anastasios Potiris<sup>1</sup>, Khaled Salech<sup>2</sup>, Peter Drakakis<sup>1</sup>, Sofia Anysiadou, Sofoklis Stavros<sup>1</sup>, Ekaterini Domali<sup>2</sup>  
<sup>1</sup>Third Department of Obstetrics and Gynecology, University General Hospital "ATTIKON", Medical School, National and Kapodistrian University of Athens, Athens, Greece.  
<sup>2</sup>First Department of Obstetrics and Gynecology, Alexandra Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.



## The controversial role of endometrial microbiome in fertility

**Argyro Papadopoulou**<sup>2</sup>, Ioannis Arkoulis<sup>1</sup>, Spyridon Topis<sup>1</sup>, Petros-Pavlos Nikolopoulos<sup>2</sup>, Petros-Pavlos Nikolopoulos<sup>2</sup>, Anastasios Potiris<sup>1</sup>, Khaled Salech<sup>2</sup>, Peter Drakakis<sup>1</sup>, Sofia Anysiadou, Sofoklis Stavros<sup>1</sup>, Ekaterini Domali<sup>2</sup>

<sup>1</sup>Third Department of Obstetrics and Gynecology, University General Hospital "ATTIKON", Medical School, National and Kapodistrian University of Athens, Athens, Greece.

<sup>2</sup>First Department of Obstetrics and Gynecology, Alexandra Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

OP9

## Mir-99a and Mir-143 expression levels in follicular and seminal fluids in infertile couples: Preliminary findings of a prospective study

**Anastasios Potiris**<sup>1</sup>, Eleni Nazou<sup>1</sup>, Ekaterini Domali<sup>2</sup>, Peter Drakakis<sup>1</sup>, Sofoklis Stavros<sup>1</sup>

<sup>1</sup>Third Department of Obstetrics and Gynecology, University General Hospital "ATTIKON", Medical School, National and Kapodistrian University of Athens, Athens, Greece.

<sup>2</sup>First Department of Obstetrics and Gynecology, Alexandra Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

OP10

12.30 - 14.00

### SESSION 1

Chairs: **Velegrakis A., Tzormpatzaki A., Drakakis I.**

- The midwife's role in IVF | **Sakaveli O.**
- Complications during natural birth | **Parasiri E.**
- Basic Principles of Cardiotocography | **Anagnostaki A.**

14.00 - 15.00

### SESSION 2 - Semen analysis

Chairs: **Berdiaki A., Asmarianaki M.**

- Can we improve semen quality? | **El Borgini A.**
- DNA fragmentation: Should it be required before IVF? | **Asmarianaki M.**
- SDI as a marker of male infertility? | **Marmara M.**

15.00 - 16.00

### SESSION 3 - Contraception

Chairs: **Kalantaridou S., Dafopoulos K.**

- Cardiovascular risk and hormonal contraception: Yes or no? First choice or progestin only pills? | **Kalantaridou S.**
- Contraception and endometriosis? | **Dafopoulos K.**
- Adolescence contraception? | **Antonakis G.**

16.00 - 16.30

### COFFEE BREAK

16.30 - 17.30

### SESSION 4 - From Reproduction to Menopause - Myths and Truths

Chairs: **Makrigiannakis A., Kalantaridou S., Asmarianaki M.**

17.30 - 18.00

### SPONSORED LECTURE I (more information on page 12)

18.00 - 19.15

### SESSION 5 - Hot Topics 1

Chairs: **Messinis I., Vlahos N.**

- The Impacts of Endocrine Disruptors Chemicals Exposure on Reproductive Outcomes | **Benkhalifa O.**
- IVF in Europe | **Sallam H.**
- Which surgery for which infertility? | **Muller M.**

19.15 - 19.45

### OPENING LECTURE

Chair: **Makrigiannakis A.**

- Chronic Stress, Aging Mechanisms, and Healthy Longevity in Women and Men | **Chrousos G.**

19.45

### OPENING CEREMONY

SATURDAY 11 | 10 | 2025

08.00 - 09.00 **ORAL PRESENTATIONS II**

Chairs: **Drakakis I.**

OP11

**Dehydroepiandrosterone (dhea) effects in the expression of receptivity and decidualization factors of the human endometrium.**

**Maria Marmara**<sup>1,2</sup>, Fanourios Makrygiannakis<sup>1,2</sup>, Thomas Vrekoussis<sup>2</sup>, Dragana Nikitovic<sup>1</sup>, Antonis Makrygiannakis<sup>2</sup> and Aikaterini Berdiaki<sup>1, 2</sup>.

<sup>1</sup>Laboratory of Histology-Embryology, Department of Morphology, Medical School, University of Crete, Heraklion, Greece, <sup>2</sup>Laboratory of Human Reproduction, Department of Obstetrics and Gynecology, Medical School, University of Crete, Heraklion, Greece

OP12

**Endometrial and seminal microbiota in infertile couples: is there a link?**

**Bompoula Maria Sotiria**<sup>1</sup>, Deligeoroglou Evangelia<sup>2,3</sup>, Krokos Panagiotis<sup>3</sup>, Bompoulas Dimitrios<sup>1</sup>, Papaioannou George<sup>4</sup>, Messaropoulos Pantelis<sup>5</sup>, Makrygiannakis Fanourios<sup>4</sup>, Makrygiannakis Antonis<sup>4</sup>, Kalantaridou N. Sophia<sup>5</sup>

<sup>1</sup>Medical School, National and Kapodistrian University of Athens, Athens, Greece, <sup>2</sup>First Department of Obstetrics and Gynecology, Papageorgiou General Hospital, Medical School, Aristotle University of Thessaloniki, Greece, <sup>3</sup>Hygeia IVF Embryogenesis, Athens, Greece, <sup>4</sup>Department of Obstetrics, Medical School, University of Crete, Heraklion, Greece, <sup>5</sup>Third Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, Attikon Hospital, Athens

OP13

**Nutritional predictors of hypothalamic inflammation: An MRS study in women with and without PCOS**

**Bompoula Maria Sotiria**<sup>1</sup>, Valsamakis Georgios<sup>2</sup>, Zouganeli Sofia<sup>3</sup>, Koussis Panagiotis<sup>4</sup>, Toulas Panagiotis<sup>4</sup>, Bompoulas Dimitrios<sup>1</sup>, Drakakis Peter<sup>5</sup>, Mastorakos George<sup>6</sup>, Kalantaridou N. Sophia<sup>5</sup>

<sup>1</sup>Medical School, National and Kapodistrian University of Athens, Athens, Greece, <sup>2</sup>Second Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens Medical School, 'Aretaieion' University Hospital, Athens, Greece, <sup>3</sup>Department of Nutrition and Dietetics, Attikon University General Hospital, Athens, Greece, <sup>4</sup>Bioiatriki SA Healthcare group, Athens, Greece, <sup>5</sup>Third Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, Attikon Hospital, Athens, Greece, <sup>6</sup>Endocrine Unit, Aretaieion University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

OP14

**Network interrogation of the progesterone-receptor-galectin-3 axis with string/stitch**

**Ioannis Boutas**, Adamantia Kontogeorgi, Fanourios Makrygiannakis, Pantelis Messaropoulos, Sophia Kalantaridou, Antonios Makrygiannakis  
Rea Maternity Hospital, Athens, Greece

09.00 - 10.00 **SESSION 6 - New predictors of IVF success**

Chairs: **Sallam H., Kolibianakis E., Domali Ek.**

- The changing Dogma of FET: HRT should not be the first choice and only be due when natural cycles are not possible? | **Venetis Ch.**
- Fertility Options in Women with Poor Ovarian Response | **Tarlatzis B.**
- Is thin endometrium a predictor for poor ART outcomes? | **Klentzeris L.**

10.00 - 10.30 **SPONSORED LECTURE II** (more information on page 12)



**SATURDAY 11 | 10 | 2025**

10.30 - 11.30 **SPONSORED SYMPOSIUM** (more information on page 12)

11.30 - 12.00 *COFFEE BREAK*

12.00 - 12.30 **SPONSORED LECTURE III** (more information on page 13)

12.30 - 13.30 **SESSION 7 - Endometriosis - Adenomyosis**

*Chairs: Sallam H., Grimbizis G.*

- Oral GnRh antagonist for treatment of Endometriosis? | **Feki A.**
- Adenomyosis and infertility. Is there a link? | **Muller M.**
- Adenomyosis: Is there a place for medical therapy? | **Makrigiannakis A.**

13.30 - 14.00 **KEYNOTE LECTURE 1**

*Chair: Messinis I.*

- Endometriosis recurrence after surgery. How often? How to manage? | **Feki A.**

14.00 - 15.00 *LIGHT LUNCH*

15.00 - 16.30 **SESSION 8 - Hot Topics 2**

*Chairs: Benkhalifa M., Loutradis D.*

- AI in ovarian stimulation | **Messini Ch.**
- Optimization of ovarian stimulation with gonadotrophins | **Messinis I.**
- Invasive vs Noninvasive PGT - from cell DNA to cell - free DNA | **Loutradis D.**
- Aging of endometrium. Does it exist? | **Makrygiannakis F.**

16.30 - 17.00 *COFFEE BREAK*

17.00 - 18.45 **SESSION 9 - Recurrent Pregnancy loss**

*Chairs: Drakakis P., Vlahos N., Stavrou S.*

- Uterine septum and myoma surgery in the treatment of recurrent pregnancy loss? To operate or not to operate? | **Grimbizis G.**
- Male contribution to RPL: mechanics, Biomarkers and therapeutic approach? | **Benkhalifa M.**
- Obesity - Implantation and early pregnancy - Does GLP1 play a role? | **Drakakis P.**
- Chronic Endometritis and RPL. | **Makrakis E.**
- Management approaches to RPL: current strategies and future directions? | **Makrigiannakis A.**

18.45 - 19.15 **KEYNOTE LECTURE 2**

*Chair: Loutradis D.*

- Targeting Aberrantly Elevated adhesion molecules as a Potential Therapy for Impaired Endometrial Selection Ability in Unexplained Recurrent Miscarriage | **Jeschke U.**

SUNDAY 12 | 10 | 2025

08.00 - 09.00 **ORAL PRESENTATIONS III**

Chair: **Nikolaou M.**

**Integrative Profiling of Endometrial Effects During Breast-Cancer Endocrine Therapy: Galectin-3 as a Translational Biomarker**

**Adamantia Kontogeorgi<sup>1</sup>**, Ioannis Boutas<sup>2</sup>, Georgios Agrogiannis<sup>5</sup>, Emmanouil Zoumakis<sup>4</sup>, Sophia Kalantaridou<sup>3</sup>, Antonios Makrigiannakis<sup>1</sup>

OP15

<sup>1</sup>Medical School University Of Crete, Heraklion , Greece, <sup>2</sup>Rea Maternity Clinic, Athens, Greece, <sup>3</sup>School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, <sup>4</sup>First Department of Pediatrics, University of Athens Medical School, Agia Sofia Hospital, Athens, Greece, <sup>5</sup>First Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece

**End stage renal failure and pregnancy management and outcomes**

**Zoi Volonaki<sup>1</sup>**, Maria Charitou<sup>1</sup>, Georgia Iakovidou<sup>1</sup>, Thomas Vrekoussis<sup>1</sup>, Maria Rasidaki<sup>1</sup>, Ioannis Drakakis<sup>1</sup>, Antonios Makrygiannakis<sup>1</sup>

OP16

<sup>1</sup>University Hospital Of Heraklion, Obstetrics and Gynecology Department, Crete, Greece

**Pregnancy complications in women with polycystic ovarian syndrome and gestational diabetes mellitus**

**E. Chalari<sup>1</sup>**, S.N. Kalantaridou<sup>2</sup>, S. Paschou<sup>3</sup>, F. Makrygiannakis<sup>4</sup>, G.K. Papaioannou<sup>1,4</sup>

OP17

<sup>1</sup>G.K. Papaioannou Private Obstetrics and Gynecology Clinic, Athens, Greece  
<sup>2</sup>Third Department of Obstetrics and Gynecology, Attikon University Hospital, Medical School of the National and Kapodistrian University of Athens, Athens, Greece  
<sup>3</sup>Endocrine Unit and Diabetes Center, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.  
<sup>4</sup>Department of Obstetrics and Gynecology, Heraklion General University Hospital, Medical School, University of Crete, Heraklion, Greece

**Combination of Continuous Use of Oral Clomiphene Citrate with Injectable Gonadotropins for Ovarian Stimulation: A Single-Center Study**

**Adamantia Kontogeorgi<sup>1</sup>**, Gkalia Tsangkalova<sup>2</sup>, Panagiota Ambatzi<sup>2</sup>, Ioannis Boutas<sup>3</sup>, Eleftherios Meridis<sup>2</sup>, Ioannis Gryparis<sup>2</sup>, Dimitrios Kalaitzis<sup>7</sup>, Melpomeni Peppas<sup>4</sup>, Sophia Kalantaridou<sup>5</sup>, Antonios Makrigiannakis<sup>1</sup>, Minas Paschopoulos<sup>6</sup>

OP18

<sup>1</sup>Medical School University Of Crete, Heraklion, Greece, <sup>2</sup>IVF Serum Advanced IVF Treatment Cente, Lykovrisi, Greece, <sup>3</sup>Rea Maternity Clinic, Athens, Greece, <sup>4</sup>2nd Department of Internal Medicine, Research Institute and Diabetes Center, National and Kapodistrian University of Athens, Attikon University Hospital, Greece, <sup>5</sup>School of Medicine, National and Kapodistrian University of Athens, Greece, <sup>6</sup>School of Medicine, University of Ioannina, Greece, <sup>7</sup>Independent Authority of Public Revenue, Greece

09.00 - 10.30 **SESSION 10 - High Risk Pregnancy**

Chairs: **Daskalakis G** , **Papaioannou G.**, **Daponte A.**

- Should we induce all diabetic patients at 38 weeks of gestation? | **Daskalakis G.**
- We can screen for pre-eclampsia but is treatment efficient? | **Gerente A.**
- What is the best strategy to prevent recurrent pre-eclampsia - aspirin, low molecular weight heparin, statins, progesterone, combination of these? | **Papaioannou G.**
- Corticosteroids: When to use and how? | **Hatzidaki E.**

10.30 - 11.00 **SPONSORED LECTURE IV** (more information on page 13)



**SUNDAY 12 | 10 | 2025**

11.00 - 11.30 *COFFEE BREAK*

11.30 - 13.30 **SESSION 11 - Fertility preservation**

*Chairs: Makrigiannakis A., Stiakaki E., Papadaki E.*

- Fertility preservation in ovarian tumors: when and what to do? | **Rodolakis A.**
- If and when should we offer fertility preservation in Endometriosis? | **N. Vlahos**
- Conservative treatment or loop in cervical dysplasia? | **Vrekoussis T.**
- Prepubertal boys' and girls' fertility preservation possibilities? | **Pelagiadis I.**
- Do all breast cancer patients need fertility preservation? | **De Bree E.**
- Hematology specialist role in fertility preservation? | **Sousos N.**
- Options and technical issues in Fertility Preservation. | **Makrigiannakis A.**

13.30 - 14.30 **SESSION 12**

*Chairs: Makrigiannakis A., Kalantaridou S., Asmarianaki M.*

14.30 - 15.00 **CLOSING REMARKS**

*Chair: A. Makrigiannakis*



# INDUSTRY SESSIONS

FRIDAY 10 | 10 | 2025

17.30 -18.00 **SPONSORED LECTURE I**

*Chair:* **Makrigiannakis A.**

- Latest Developments in the Treatment of Vasomotor Symptoms During Menopause  
**Kalantaridou S.**

Sponsored by:  
 **astellas**

SATURDAY 11 | 10 | 2025

10.00 -10.30 **SPONSORED LECTURE II - RSV vaccine**

*Chair:* **Makrigiannakis A.**

- RSVPreF: The gift of maternal antibodies — Protecting infants against RSV from the very first breath  
**Vergadi E.**

Sponsored by:  
 **Pfizer**

10.30 -11.30 **SPONSORED SYMPOSIUM - Follitropin delta: Advances in IVF treatment**

*Chair:* **Sfakianoudis K.**

- Follitropin delta: Scientific data and guidelines  
**Kolibianakis E.**
- The role of follitropin delta in daily practice  
**Lainas G.**

Sponsored by:

**FERRING**  
ΦΑΡΜΑΚΕΥΤΙΚΑ



## SATURDAY 11 | 10 | 2025

### 12.00-12.30 **SPONSORED LECTURE III**

*Chair:* **Tarlatzis B.**

- Interplay of hormones in stimulated cycles: Rationale, clinical necessity and therapeutic options

**Pirtea P.**

*Sponsored by:*



## SUNDAY 12 | 10 | 2025

### 10.30-11.00 **SPONSORED LECTURE IV**

*Chair:* **Sakellarakis G., Terzakis G.**

- PICO for the Prevention and Treatment of Surgical Site Infections in Modern Obstetrics and Gynaecology

**Petousis St.**


*Sponsored by:*

**Smith+Nephew**

## ΝΕΟΙ ΟΡΙΖΟΝΤΕΣ ΣΤΟΝ ΓΕΝΕΤΙΚΟ ΕΛΕΓΧΟ

ΜΗ ΕΠΕΜΒΑΤΙΚΟΣ  
ΠΡΟΓΕΝΝΗΤΙΚΟΣ ΕΛΕΓΧΟΣ  
**PrenaTest®**  
Αξιόπιστο | Γρήγορο | Ασφαλές

**1 TEST**  
**8 ΕΠΙΛΟΓΕΣ**



- ✓ **ΝΕΟΣ ΜΟΡΙΑΚΟΣ ΚΑΡΥΟΤΥΠΟΣ**
  - GENETISURE CYTO CGH MICROARRAY BY AGILENT
  - ΔΙΠΛΑΣΙΑΣΜΟΙ / ΕΛΛΕΙΨΕΙΣ
  - ΓΟΝΙΔΙΑ ΣΤΟΧΟΙ: 3644
- ✓ **CLINICAL EXOME ANALYSIS by AGILENT**
  - ΓΟΝΙΔΙΑ ΣΤΟΧΟΙ: ~4800
- ✓ **WHOLE EXOME ANALYSIS by AGILENT**
  - ΓΟΝΙΔΙΑ ΣΤΟΧΟΙ: ~20.000
- ✓ **ΚΛΗΡΟΝΟΜΙΚΟΙ ΚΑΡΚΙΝΟΙ**
  - BRCA 1/2
  - PANEL ΚΛΗΡΟΝΟΜΙΚΩΝ ΚΑΡΚΙΝΩΝ
- ✓ **ΜΟΝΟΓΟΝΙΔΙΑΚΑ ΝΟΣΗΜΑΤΑ**
  - ΚΥΣΤΙΚΗ ΙΝΩΣΗ
  - ΜΕΣΟΓΕΙΑΚΗ ΑΝΑΙΜΙΑ
  - FRAGILE X
  - ΝΩΤΙΑΙΑ ΜΥΪΚΗ ΑΤΡΟΦΙΑ (S.M.A.)
- ✓ **ΜΟΡΙΑΚΟΣ ΕΛΕΓΧΟΣ ΣΥΓΓΕΝΩΝ ΛΟΙΜΩΞΕΩΝ**
  - T.O.R.C.H
- ✓ **ΕΛΕΓΧΟΣ ΠΡΟΕΚΚΛΑΜΨΙΑΣ**
  - sFlt-1/PIGF
- ✓ **HPV**

# GENERAL INFORMATION

## Crete | Heraklion

Crete, the island of king Minos in the southern part of the Aegean Sea, is full of natural beauties to explore and enjoy. Heraklion is the capital of Crete and one of the Mediterranean region's most fascinating and vibrant cities.

Even though it has an often crowded city center, the main Town keeps its fairytale vibe. Strolling around the town, you will come across Koules fortress, at the Venetian port, Turkish and Venetian fountains, Venetian buildings, the Venetian Loggia and museums, such as the Archaeological Museum, the Historical Museum and the Museum of Natural History.

## Venue

The Meeting is held in Heraklion, Ibis Styles Heraklion Central Hotel.

**A.** Koroneou 26 & Agiou Titou, 71202, Heraklion Crete

**T.** +30 2810 28 20 20

**W.** [www.centralhotelheraklion.com](http://www.centralhotelheraklion.com)

## Dates

The Meeting is held on October 10-12.

## Meeting's website

The official website of 9th SSRHR meeting's is: [www.ssrhrmeetings.com](http://www.ssrhrmeetings.com)

## Language

ENGLISH is the official language of the Meeting. No simultaneous interpretation will be provided.

## Speakers preview desk

A Speaker Preview Desk will be operating throughout the Meeting. Speakers and presenting authors are kindly requested to hand in their presentation (PowerPoint) at least one (1) hour before their scheduled presentation time to the Speakers Preview Desk.


For presentations scheduled early in the morning, you are kindly requested to hand in your presentation the day before.

All MS-PowerPoint versions will be available.

The following equipment will also be available: laptop and laser pointer. We would like to kindly draw your attention to the importance of complying with your session's schedule, in order to ensure the smooth running of the Scientific Program.

## CME Accreditation

The attendance of the 9th SSRHR Meeting is accredited with 18.5 ECMECs by the EACCME (European Accreditation Council for Continuing Medical Education).



# GENERAL INFORMATION

## I. REGISTRATION

### Foreign Societies of Gynecology (for non SFEE MEMBERS)

€ 248,00 (Taxes Included)

The registration fees for participants include:

- Access to the scientific sessions and exhibition
- Meeting material
- Certificate of attendance
- Coffee breaks & Lunch

### Greek Societies of Gynecology

€ 173,60 (Taxes Included)

The registration fees for participants include:

- Access to the scientific sessions and exhibition
- Meeting material
- Certificate of attendance

### Food Services

(Coffee breaks & Lunch)

€ 70,00 (Taxes Included)

## II. ACCOMMODATION

### Hotel

### Single Room

Ibis Styles Heraklion Central –  
MEETING HOTEL (ON BB BASIS)

€ 125

### Certificate of attendance

A certificate of attendance will be sent to each registered participant, after the end of the Meeting. We would be grateful if you could take a few minutes to answer an online survey that will be sent to you shortly after the end of the meeting. Your valuable feedback will help us to improve the organisation and quality of the next SSRHR meeting.

### Secretariat and hospitality desk

The Meeting Secretariat desk will be located nearby the main Meeting Hall and will operate throughout the Meeting hours.

### Internet access

Wireless internet connection is available in all Meeting's areas.

### Trade exhibition

An exhibition of scientific products, pharmaceuticals, instruments, equipment and relevant materials will be organized at the Meeting Venue.

### Professional Congress Organizers



A: 17 Asklipiou str, 106 80 Athens, Greece  
T: +30 210 3634944 E: info@era.gr  
W: www.era.gr

# ACKNOWLEDGEMENTS

The Organizing Committee of the 9th SSRHR Meeting would like to thank its sponsors for their contribution





[www.atg-labs.gr](http://www.atg-labs.gr) • [www.biopathologiki.gr](http://www.biopathologiki.gr)

## Υψηλή Εξειδίκευση Άμεση Επιστημονική Υποστήριξη Μέγιστη Αξιοπιστία

- Μη Επεμβατικός Προγεννητικός Έλεγχος
- Προγεννητικός Γενετικός Έλεγχος
- Προεμφυτευτικός Γενετικός Έλεγχος
- Γενετικός Έλεγχος Υπογονιμότητας & Καθ' Ήξιν Αποβολών
- Έλεγχος Γενετικών Νοσημάτων/Συνδρόμων
- Γενετικός Έλεγχος Κληρονομικού Καρκίνου & Συμπαγών Όγκων
- Εξειδικευμένες Εξετάσεις Βιοπαθολογίας
- Κυτταρολογικός Έλεγχος
- Κλινική Γενετική & Γενετική Συμβουλευτική



**Access To Genome**  
CLINICAL LABORATORY GENETICS

# reimagining the future, time and again

Η Merck από τη «γέννησή» της βρίσκεται στην πρώτη γραμμή των θεραπειών γονιμότητας. Σήμερα συνεχίζουμε τη δέσμευσή μας για επιστημονική αριστεία και φανταζόμαστε νέες δυνατότητες για τους ασθενείς του αύριο.

Αδιάλειπτα υποστηρίζουμε με συνέπεια τους ειδικούς στη γονιμότητα σε όλο τον κόσμο, ώστε να προσφέρουν στους ασθενείς τους, την καλύτερη φροντίδα και τη δυνατότητα να πραγματοποιήσουν το όνειρό τους στην απόκτηση οικογένειας.

**Fertility by Merck.  
Enabling wonders, together.**




GC-NONF-00112.11/2023

**MERCK**

Λ. Κηφισίας 41-45 (κτήριο Β)  
15123, Μαρούσι, Αττική  
τηλ: 210 6165100  
[www.merck.gr](http://www.merck.gr)



# NOTES




A series of horizontal dotted lines for writing notes, spanning the width of the page.

# NOTES

A series of horizontal dotted lines for writing notes.

# NOTES



A series of horizontal dotted lines for writing notes, spanning the width of the page.

**Ivor**<sup>®</sup>  
Bemiparin sodium

**IvorMAX**<sup>®</sup>  
Bemiparin sodium



#### ΣΥΝΟΠΤΙΚΗ ΠΕΡΙΓΡΑΦΗ ΤΩΝ ΧΑΡΑΚΤΗΡΙΣΤΙΚΩΝ ΤΟΥ ΠΡΟΪΟΝΤΟΣ

**ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ:** Ivor 2.500 IU anti-Xa/0,2 ml ενέσιμου διαλύματος σε προγεμισμένες σύριγγες **ΠΟΙΟΤΙΚΗ & ΠΟΣΙΟΤΙΚΗ ΣΥΝΘΕΣΗ:** Bemiparin sodium: 2.500 IU (anti Factor Xa\*) ανά 0,2 ml προγεμισμένη σύριγγα (ισοδύναμη με 12.500 IU (anti Factor Xa\*) ανά ml ενέσιμου διαλύματος). Η δραστηριότητα περιγράφεται σε Διεθνείς μονάδες anti-Factor Xa δραστηριότητας (IU) με βάση το Πρώτο Διεθνές Πρότυπο Αναφοράς Ηπαρίνης Χαμηλού Μοριακού Βάρους. Για τον πλήρη κατάλογο των εκδόχων, βλ. παράγραφο 6.1. **ΣΥΣΚΕΥΑΣΙΕΣ/ΤΙΜΕΣ:** IVOR 2.500 IU anti-Xa/0,2 ml BT x 2 PF.SYR Λ.Τ.: 5,83 €

**ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ:** Ivor 3.500 IU anti-Xa/0,2 ml ενέσιμου διαλύματος σε προγεμισμένες σύριγγες **ΠΟΙΟΤΙΚΗ & ΠΟΣΙΟΤΙΚΗ ΣΥΝΘΕΣΗ:** Bemiparin sodium: 3.500 IU (anti Factor Xa\*) ανά 0,2 ml προγεμισμένη σύριγγα (ισοδύναμη με 17.500 IU (anti Factor Xa\*) ανά ml ενέσιμου διαλύματος). Η δραστηριότητα περιγράφεται σε Διεθνείς μονάδες anti-Factor Xa δραστηριότητας (IU) με βάση το Πρώτο Διεθνές Πρότυπο Αναφοράς Ηπαρίνης Χαμηλού Μοριακού Βάρους. Για τον πλήρη κατάλογο των εκδόχων, βλ. παράγραφο 6.1. **ΣΥΣΚΕΥΑΣΙΕΣ/ΤΙΜΕΣ:** IVOR 3.500 IU anti-Xa/0,2 ml BT x 2 PF.SYR Λ.Τ.: 10,74 € BT x 30 PF.SYR Λ.Τ.: 120,83 €

**ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ:** Ivormax 25.000 IU anti-Xa/ml ενέσιμου διαλύματος σε προγεμισμένες σύριγγες **ΠΟΙΟΤΙΚΗ & ΠΟΣΙΟΤΙΚΗ ΣΥΝΘΕΣΗ:** Bemiparin sodium: 25.000 IU (anti-Factor Xa\*) ανά ml ενέσιμου διαλύματος. Ισοδύναμη με: 5.000 IU (anti-Factor Xa) ανά 0,2 ml προγεμισμένη σύριγγα, 7.500 IU (anti-Factor Xa) ανά 0,3 ml προγεμισμένη σύριγγα, 10.000 IU (anti-Factor Xa) ανά 0,4 ml προγεμισμένη σύριγγα. \* Η δραστηριότητα περιγράφεται σε Διεθνείς μονάδες anti-Factor Xa δραστηριότητας (IU) με βάση το Πρώτο Διεθνές Πρότυπο Αναφοράς Ηπαρίνης Χαμηλού Μοριακού Βάρους. Για τον πλήρη κατάλογο των εκδόχων, βλ. παράγραφο 6.1. **ΣΥΣΚΕΥΑΣΙΕΣ/ΤΙΜΕΣ:** IVORMAX 25.000 IU anti-Xa/ml, BTx2PF.SYRx0,2ML Λ.Τ.: 23,40€, IVORMAX 25.000 IU anti-Xa/ml, BTx2PF.SYRx0,3ML Λ.Τ.: 26,43€, IVORMAX 25.000 IU anti-Xa/ml BTx2PF.SYRx0,4ML Λ.Τ.: 23,33€

**ΦΑΡΜΑΚΟΤΕΧΝΙΚΗ ΜΟΡΦΗ:** Ενέσιμο διάλυμα σε προγεμισμένες σύριγγες. (Αχρωμο ή ελαφρώς κιτρινωπό, διαυγές διάλυμα, ελεύθερο ορατών σωματιδίων). **ΚΑΤΟΧΟΣ ΤΗΣ ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ:** Προϊόν της LABORATORIOS FARMACEUTICOS ROVI S.A., ΙΣΠΑΝΙΑ. Κάτοχος αδείας κυκλοφορίας: BIANEX A.E., Οδός Βαρυμύμης 8, 14671 Ν. Ερυθραία, Κηφισιά, Τηλ. 210800911. **ΑΡΙΘΜΟΣ(ΟΙ) ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ:** 24481/26-02-2020, 24482/26-02-2020, 24483/26-02-2020.

**ΗΜΕΡΟΜΗΝΙΑ ΑΝΑΘΕΩΡΗΣΗΣ ΤΟΥ ΚΕΙΜΕΝΟΥ:** 06-04-2023 (Ivor), 12-07-2023 (Ivormax)

**ΤΡΟΠΟΣ ΔΙΑΘΕΣΗΣ:** Φαρμακευτικό προϊόν για το οποίο απαιτείται ιατρική συνταγή

Περαιτέρω πληροφορίες διατίθενται από τον ΚΑΚ κατόπιν αιτήσεως.



**BIANEX** A.E.  
ΒΙΟΜΗΧΑΝΙΑ ΦΑΡΜΑΚΩΝ  
ΕΤΑΙΡΕΙΑ ΤΟΥ ΟΜΙΛΟΥ ΓΙΑΝΝΑΚΟΠΟΥΛΟΥ

BIANEX A.E. - Έδρα : Οδός Βαρυμύμης 8, 14671 Ν. Ερυθραία, Κηφισιά  
Ταχ. Θυρίδα 52894, 146 10 Ν. Ερυθραία • Τηλ. : 210 8009111 • Fax: 210 8071573  
E-mail: mailbox@vianex.gr • WEBSITE: www.vianex.gr  
ΘΕΣΣΑΛΟΝΙΚΗ: Ακαδημίου 113, 562 24 Εύμοσης Θεσσαλονίκης • Τηλ.: 2310 861683

ΑΡ. Γ.Ε.ΜΗ. 000274201000

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και  
Αναφέρετε  
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για  
ΟΛΑ τα φάρμακα  
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»



VE-24236-IVO-9/2024

# 9<sup>th</sup> SSRHR Meeting

Controversies in  
Human Reproduction

